Crinetics Pharmaceuticals Files 8-K
Ticker: CRNX · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $350.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials
Related Tickers: CRNX
TL;DR
CRNX filed an 8-K, mostly standard financial exhibits. Nothing major to see here.
AI Summary
On June 21, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure rather than a specific material event. No new material agreements, executive changes, or significant financial transactions were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard disclosure for Crinetics Pharmaceuticals, Inc., providing updates on financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no indication of significant new risks or material adverse events.
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- June 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38583 (identifier) — Commission File Number
- 26-3744114 (identifier) — IRS Employer Identification No.
- 6055 Lusk Boulevard (address) — Address of Principal Executive Offices
- San Diego (location) — City of Principal Executive Offices
- California (location) — State of Principal Executive Offices
- 92121 (zip_code) — Zip Code of Principal Executive Offices
- ( 858 ) 450-6464 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Crinetics Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of June 21, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 21, 2024.
In which state is Crinetics Pharmaceuticals, Inc. incorporated?
Crinetics Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Crinetics Pharmaceuticals, Inc.?
The principal executive office address is 6055 Lusk Boulevard, San Diego, California, 92121.
Does this filing indicate any specific material event or transaction?
Based on the provided excerpt, the filing indicates 'Other Events' and 'Financial Statements and Exhibits,' suggesting a routine disclosure rather than a specific, singular material event.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-06-21 17:24:56
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
- $350.0 million — registering the offer and sale of up to $350.0 million of the Shares. Item9.01 Financial Sta
Filing Documents
- d781699d8k.htm (8-K) — 27KB
- d781699dex11.htm (EX-1.1) — 215KB
- d781699dex51.htm (EX-5.1) — 9KB
- 0001193125-24-165903.txt ( ) — 432KB
- crnx-20240621.xsd (EX-101.SCH) — 2KB
- crnx-20240621_lab.xml (EX-101.LAB) — 17KB
- crnx-20240621_pre.xml (EX-101.PRE) — 11KB
- d781699d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement, dated June 21, 2024, by and among Crinetics Pharmaceuticals, Inc., Leerink Partners LLC and Cantor Fitzgerald & Co. 5.1 Opinion of Morrison & Foerster LLP. 23.1 Consent of Morrison & Foerster LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: June 21, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)